Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Lawsuits claiming Tylenol causes autism lack scientific support, judge finds

Published 12/19/2023, 03:59 PM
Updated 12/19/2023, 04:06 PM
© Reuters. Tylenol brand pain relief medicine is seen on display at the Safeway store in Wheaton, Maryland February 13, 2015.    REUTERS/Gary Cameron/ File Photo

By Brendan Pierson

(Reuters) - A judge has barred expert witnesses from testifying that Johnson & Johnson (NYSE:JNJ) spin-off Kenvue (NYSE:KVUE)'s painkiller Tylenol can cause autism if mothers take it during pregnancy, finding that they failed to support their conclusions with scientific evidence.

The ruling on Monday by U.S. District Judge Denise Cote in Manhattan federal court likely means the end of a consolidated mass tort litigation of about 500 lawsuits over the popular over-the-counter drug, unless plaintiffs get it reversed on appeal.

Cote, in a 148-page ruling, found that none of the five expert witnesses proposed by the plaintiffs had offered a sound scientific methodology to support their opinion that Tylenol's active ingredient, acetaminophen, could cause autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD).

"Instead, the unstructured approach adopted by the plaintiffs' experts permitted cherry-picking, allowed a results-driven analysis, and obscured the complexities, inconsistencies, and weaknesses in the underlying data," she wrote.

Kenvue, which was Johnson & Johnson's consumer health unit before it was spun off in August, in a statement said it will move to dismiss all the cases in light of the ruling. Its shares rose about 4% in Tuesday trading following the decision.

"These lawsuits have created confusion on the safety of one of the most studied medications in history," the company said. "Acetaminophen is recommended by doctors as a first-line treatment option for people who have a fever or are experiencing pain during pregnancy. It is scientifically known that not treating these conditions may have serious health consequences for both mother and baby."

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Lawyers for the plaintiffs did not immediately respond to requests for comment.

The lawsuits also targeted retailers that sold their own generic versions of Tylenol, including CVS, Walgreens and Walmart (NYSE:WMT). CVS and Walgreens declined to comment on the decision, and Walmart did not immediately respond to a request for comment.

Product liability lawsuits, like the ones over Tylenol, rely on experts to establish that the product is capable of causing the alleged harm. Federal judges decide what expert testimony is allowed, based on whether it meets scientific standards first laid out by the U.S. Supreme Court in its 1993 ruling in Daubert v. Merrell Dow Pharmaceuticals.

The multidistrict litigation was consolidated before Cote in October 2022. Plaintiffs had begun filing lawsuits earlier that year, claiming that the retailers failed to warn pregnant users of acetaminophen products about the neurological risks to the fetus.

Health experts advise pregnant women to take acetaminophen rather than aspirin or ibuprofen, which can cause fetal organ damage.

While some studies have found an association between the disorders and acetaminophen use in pregnancy, researchers have cautioned that other, underlying factors could be responsible and that more study is needed.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.